Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung ...

Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

Data from the HARMONi trial suggest that outcomes may differ between patients in China and those in North America or Europe.

B96 to be featured in Presidential Symposium, underscoring the impact of KEYTRUDA® (pembrolizumab) in certain bladder and ovarian cancersData from multiple investigational medicines from Merck’s ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute ...

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to become a ...